Several developments on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] have recently occurred in Japan. For GEP-NETs diagnosis and treatment, grading and correct histological diagnosis according to the WHO 2010 classification is important. Regarding the histological diagnosis, the advent of endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) has enabled correct pathological diagnosis and suitable treatment for the affected tissue. Furthermore, EUS-FNA has also facilitates the assessment of the presence or absence of gene mutations. In addition, patients with PNETs who have a well-differentiated neuroendocrine tumor (NET) showing a Ki-67 index of higher than 20% according to the WHO 2010 classification, have also been identified, and their responses to treatment were found to be different from those of patients with poorlydifferentiated neuroendocrine carcinoma (NEC). Therefore, the concept of NET G3 was proposed and WHO criteria has been revised in 2017 regarding with PNETs (PNENs). Additionally, somatostatin type 2 receptor is expressed in several cases of NET, and somatostatin receptor scintigraphy ( 111 In-octreoscan) has also been approved in Japan. Finally, regarding the treatment strategy for GEP-NETs, the management of liver metastasis is important. The advent of novel molecular-targeted agents has dramatically improved the prognosis of advanced GEP-NETs. Further, the efficacy and safety of lanreotide, somatostatin analogue, indicated its usefulness as a treatment option for Japanese NET patients. Multimodality therapy that accounts for the tumor stage, degree of tumor differentiation, tumor volume, and speed of tumor growth is required.
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